We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Rapid Diagnostic for C. difficile Eliminates Extraction Step

By LabMedica International staff writers
Posted on 19 May 2011
A new Clostridium difficile diagnostic test enables processing of up to 94 patient specimens in about an hour.

The Simplexa C. More...
difficile universal direct test is performed on liquid or unformed human stool samples, and detects toxin-producing strains of C. difficile, including NAP1/B1/027. The new CE marked in vitro diagnostic (IVD) test enables fast, high volume lab testing, eliminating the traditional extraction step.

The C. difficile diagnostic is the first test from the Focus Diagnostics (Cypress CA, USA) Simplexa product line for the hospital-acquired infection (HAI) market. It was unveiled by Focus together with the CE marked Simplexa Epstein Barr (EBV) and BK Virus tests during the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Tradeshow, which took place May 7-10, 2011, in Milan (Italy). The three Simplexa tests are CE marked and available in Europe.

Simplexa tests are run on the 3M Integrated Cycler and employ real-time polymerase chain reaction (RT-PCR) to detect viruses, bacteria, and other agents qualitatively and quantitatively.

C. difficile infection (CDI) is a bacterial infection that generally affects patients over 65 in age, on prolonged use of broad-spectrum antibiotics, and those who have recently undergone gastrointestinal surgery or are immunocompromised. In major European Union (EU) countries, such as Belgium, Denmark, France, Germany, Italy, Netherlands, Spain and the United Kingdom, CDI is estimated to be responsible for 1.1 in 1,000 hospital admissions and is expected to double over the next four decades.

"Clostridium difficile is a common cause of antibiotic-associated diarrhea and an extremely important and serious hospital-acquired infection," said Jay M. Lieberman, MD, medical director for Quest Diagnostics (Madison, NJ, USA) and Focus Diagnostics. "C. difficile infections (CDI) range in severity from mild diarrhea to life-threatening pseudomembranous colitis, and result in significant suffering and deaths. Timely diagnosis is essential for clinicians when treating patients presenting with possible C. difficile disease." Focus Diagnostics is a wholly owned subsidiary of Quest Diagnostics.

Related Links:
Focus Diagnostics
Quest Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automated Clinical Chemistry Analyzer
Envoy 500+
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.